The UroOnc Minute: Salvage Focal Therapy for Radiorecurrent Prostate Cancer, with Alexander Light, MBBS

Welcome back to The UroOnc Minute!

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, continues coverage from the 41st Annual European Association of Urology Congress in London, speaking with Alexander Light, MBBS, about evolving strategies for salvage treatment in patients with radiorecurrent prostate cancer. Light is a clinical research fellow and PhD candidate at Imperial College London.

Light discusses findings from a multicenter international analysis comparing salvage focal therapy (sFT) with salvage radical prostatectomy (sRP),¹ an area where high-quality comparative data have historically been limited. Drawing on collaborative efforts across the UK and Europe, the study demonstrated excellent long-term cancer-specific survival at 10 years with both approaches (92% sFT vs 99% sRP), while highlighting the lower morbidity profile associated with focal therapy (any complication, adjusted odds ratio, 24.20; 95% CI, 12.94 to 45.27; P < .001). These findings position salvage focal therapy as a promising alternative, particularly for patients who may not be candidates for or are unwilling to undergo surgery.

The conversation explores how patient selection and treatment planning are critical to the success of focal approaches in the salvage setting. Light emphasizes the importance of advanced imaging, including MRI and PET-based modalities, alongside confirmatory biopsies to ensure disease localization prior to treatment. In practice, techniques such as high-intensity focused ultrasound (HIFU) and cryotherapy are used in a targeted manner to ablate only the cancerous region of the prostate while preserving surrounding tissue. Compared with the primary treatment setting, salvage procedures require a more cautious approach due to prior radiation exposure, with adjustments in energy delivery and treatment extent to mitigate risks such as fistula formation. Despite this more conservative strategy, outcomes from the study suggest maintained efficacy alongside improved safety.

Looking ahead, Light highlights ongoing efforts to expand the evidence base through large prospective registries, including data collected through UK-based initiatives. These datasets are expected to play a key role in refining patient selection and enabling future comparisons with other emerging salvage strategies, such as re-irradiation. He also underscores the growing impact of advanced imaging, particularly PSMA-PET, in better defining recurrent disease and potentially reshaping treatment paradigms. As longer-term follow-up accrues and diagnostic tools continue to evolve, the field is poised to further clarify the optimal role of focal therapy within the broader landscape of salvage options for prostate cancer recurrence.

REFERENCE

1. Light A, Peters M, Arya M, et al. Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer. JAMA Oncol. 2026:e256448. doi:10.1001/jamaoncol.2025.6448